Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technology
Biotech firm Factor Bioscience has filed a lawsuit against Cellectis and AstraZeneca, accusing the companies of allegedly infringing three patents related to its gene-editing technology used in cancer treatments. The lawsuit, filed in the District federal Court, alleges that Cellectis copied Factor’s technology for designing gene-edited cells for cancer therapies. Cellectis licenses its gene-editing technology […]